Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 169

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 169
---
 DiamiR’s product, if any of its product candidates are approved, may depend on the availability of adequate reimbursement to its customers from third-party payers, including government programs such as Medicare and Medicaid, private insurance plans, and managed care programs.

Maintaining and growing sales of its approved products depends in part
on the availability of adequate coverage and reimbursement of its products by third-party payers, including government programs such as
Medicare and Medicaid, private insurance plans and managed care programs. Hospitals, clinical laboratories and other healthcare provider
customers that may purchase its products generally bill various third-party payers to reimburse all or a portion of the costs and fees
associated with diagnostic tests, including the cost of the purchase of its products. DiamiR’s customers’ access to adequate
reimbursement by government and private insurance plans is central to the acceptance of its products. DiamiR may be unable to monetize
its commercial products on a profitable basis if third-party payers refuse to cover its products or pay DiamiR low levels of reimbursement,
or if its costs of production increases faster than increases in reimbursement levels.

<div align='center'>89</div>

Additionally, third-party payers are increasingly reducing reimbursement
for medical products and services. In addition, the U.S. government, state legislatures, and foreign governments have and may continue
to implement cost-containment measures and more restrictive policies, including price controls and restrictions on reimbursement. Government
authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular
products. Further, the Budget Control Act of 2011 (the “Budget Control Act”) established a process to reduce federal
budget deficits through an automatic “sequestration” process if deficit reductions targets are not otherwise reached. Under
the terms of the Budget Control Act, sequestration imposes cuts to a wide range of federal programs, including Medicare, which is subject
to a two percent cut. The Bipartisan Budget Act of 2013 extended the two percent sequestration cut for Medicare through fiscal
year 2023, and a bill signed by President Obama on February 15, 2014 further extended this cut for an additional year, through fiscal
year 2024. The Coronavirus Aid, Relief, and Economic Security (CARES) Act, signed into law in March 2020, included critical relief
from sequestration cuts as it applies to Medicare payments, exempting Medicare from the effects of sequestration from May